儿童慢性髓性白血病伊马替尼治疗药物监测的实践实施与结果解读
该研究基于多中心CML-PAED-II研究及后续注册研究的真实世界数据,纳入72例患儿的269份伊马替尼谷浓度和50例患者的BCR::ABL1/ABL1转录本比值,评估指数外推法估算谷浓度的可行性,采用线性混合效应模型分析浓度预测因素,并分析谷浓度与分子学缓解的关联及儿科特异性目标阈值,最终整合为伊马替尼TDM临床算法。
要点
- 给予的伊马替尼剂量是血浆浓度的主要预测因素。
- 成人来源的1000 ng/mL目标阈值在儿科实践中被证明适用。
- 较高谷浓度倾向于与更快的初始分子学缓解相关。
核心结论
- 所开发的算法支持在儿科伊马替尼治疗中使用TDM,有助于早期识别暴露低于目标浓度及疗效变异,以进一步改善治疗结局。
研究设计与样本
- 基于多中心CML-PAED-II研究及后续注册研究的真实世界儿科数据,纳入72例患者的269份伊马替尼谷浓度和50例患者的BCR::ABL1/ABL1转录本比值。
- 评估指数外推法估算可解读的伊马替尼谷浓度,并使用线性混合效应模型评估血浆浓度预测因素。
- 分析伊马替尼谷浓度与分子学缓解的关联,并评估儿科特异性目标阈值。
- 将研究发现整合为伊马替尼TDM临床应用的算法。
主要发现
- 给予的伊马替尼剂量是血浆浓度的主要预测因素。
- 较高谷浓度倾向于与更快的初始分子学缓解相关。
- 成人来源的1000 ng/mL目标阈值在儿科实践中被证明适用。
关键数值与推荐
- 成人来源的目标阈值1000 ng/mL在儿科实践中被证明适用。
临床怎么用
- 所开发的算法概述了临床决策点及其后果,是口服抗肿瘤治疗期间现有强化临床药理/药学照护项目的关键要素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND INTRODUCTION: Imatinib (IMA) revolutionised the treatment of chronic myeloid leukaemia (CML). Therapeutic drug monitoring (TDM) of IMA is recommended to improve treatment outcomes in adults, but guidance for reliable interpretation of plasma concentrations in children is limited. Using real-world paediatric data, we aimed to develop a practical algorithm with recommendations for an IMA TDM procedure in paediatric oncology. METHODS: Imatinib plasma concentrations and clinical data were collected from patients enrolled in the multicentre CML-PAED-II study and subsequent registry. We evaluated the method of exponential extrapolation for estimating interpretable IMA trough concentrations and used linear mixed effects models to assess plasma concentration predictors. Associations between IMA trough concentrations and molecular response were analysed, and a paediatric-specific target threshold was evaluated. Findings were integrated into an algorithm for clinical application of IMA TDM. RESULTS: In total, 269 IMA trough concentrations from 72 patients and BCR::ABL1/ABL1 transcript ratios from 50 patients were included. Using a correction tool, we obtained estimates of trough concentration by exponential extrapolation. Administered IMA dose was the main predictor of plasma concentrations. Higher trough concentrations tended to correlate with faster initial molecular response. The adult-derived target threshold of 1000 ng/mL proved applicable in paediatric practice. The developed algorithm outlines clinical decision points and consequences, which are key elements of existing intensified clinical pharmacological/pharmaceutical care programmes during oral antitumour therapy. CONCLUSION: The algorithm supports the use of TDM during paediatric IMA treatment, enabling early identification of exposure below the targeted concentration and variations in treatment efficacy to further improve treatment outcomes.
引用
- Lensker P, Gottschalk A, Zerjatke T, et al. Therapeutic Drug Monitoring of Imatinib in Paediatric Chronic Myeloid Leukaemia: Towards Practical Implementation and Interpretation of Measured Plasma Concentrations. Clin Pharmacokinet. 2026. PMID: 42154176. doi:10.1007/s40262-026-01644-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。